Camber Specialty Marks First Day 1 Injectable Launch
Camber Specialty, a division of Camber Pharmaceuticals, has launched Sugammadex Injection [soo-GAM-ma-dex], its first Day 1 injectable product.
“We are proud to achieve our first Day 1 launch with Sugammadex Injection,” said Tom DeStefano, Vice President of Specialty Sales. “This milestone reflects our commitment to expanding access to high-quality injectable products that support healthcare providers and their patients.”
Generic for Bridion®, Sugammadex Injection is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adult and pediatric patients 2 years of age and older undergoing surgery.
Sugammadex Injection is available in:
- 200 mg/2 mL (100 mg/mL) | 10 Single-Dose 2 mL Vials
- 500 mg/5 mL (100 mg/mL) | 10 Single-Dose 5 mL Vials
To learn more about Sugammadex Injection, click here.
Recent articles
- Camber Specialty Marks First Day 1 Injectable Launch
- New to Camber’s Portfolio: Olmesartan medoxomil, Amlodipine and Hydrochlorothiazide Tablets
- Camber Pharmaceuticals Honored as Second Merit Finalist at 2026 DIANA Awards
- Camber Launches Nitazoxanide Tablets
- Cisatracurium Besylate Injection, USP Added to Camber’s Portfolio
- Camber Welcomes Summer 2026 Intern Class






